Review
Copyright ©The Author(s) 2020.
World J Clin Cases. May 26, 2020; 8(10): 1767-1792
Published online May 26, 2020. doi: 10.12998/wjcc.v8.i10.1767
Table 8  In vivo miscellaneous effects and related mechanisms of action of oleanolic acid and its natural and synthetic derivatives (2014-2020)
Disease model/ physiologyEffectMechanism
CompoundDose/IC50 /Ki.Ref.
↑↑↑↓↓↓
AtherosclerosisAnti-atheroscleroticAng1-7, ANG, NO, eNOSIL-1β, TNF-α, and IL-6OA0-160 µmol/L[29]
Immune suppressionZFP-459, FMO-2OA-Xs[116]
T. cruzi, L. braziliensis, L. infantumAnti-protozoal-OA, OA-X3.3-89 µmol/L[138]
Leishmania speciesAnti-parasiticCYP51, ergosterol synthesisOA30.4-68.7 µmol/L[139]
P. berghei malariaAnti-malariaTNF-α, IL-6, IL-10, hepcidinOA34 mg/kg, 5 d[140]
HBVAnti-viralHBS-Ag, HBE-Ag, HBV DNA replicationOA-Xs8.6-38.1[141]
Allergic conjunctivitisAnti-allergic and anti-inflammatoryIL-10Allergen-specific IgGs, sPLA2 -IIA, Th2, RWP-T-Cell dif, EOL-1 , IL-33, MCP-1OA50 mg/kg·d, 5 d after sens[142]
AsthmaAnti-asthmatictBET, FOX-P3IL-5, IL-13, IL-17, OVA-IgE, GATA-3, RORγt,OA2 or 20 mg/kg·2 d, 5 wk[143]
AtherosclerosisAnti-artheroscleroticNRF-2, HO-1, SOX, NO, CAT, GPX, GSH, HDLLOX, NADPH Ox, LDL, TC, TG, pGP91, pP67, pP7OA15-50 mg/kg·d, 3 wk; 5-20 µmol/L[144]
Vascular injuryPrevent endothelial oxLDL effectCASP, NO, pAKT, peNOS,OA-Xn5 and 100 µmol/L[145]
Low-density lipoprotein receptor knockout (LDLR −/− ) miceReview AtheroscleroticAdipoR1, PPAR-γAdipoR2, TC, LDL-COA25 mg/kg·d, 5 wk[146]
Myocardial injuryCardioprotection, hyperglycemia-induced myocardial injuryCASP-3/9, BAX, pERK1/2, HOMER-1α, ERK1/2, SIRT1BCL-2, ROSOA-Xn12.5-50 µmol/L[147]
Carotid artery injuryProteccts diabetes induced artery injurybody weights, serum NOendothelin 1, IL-1β, IL-6 , IL-18, NLRP-3, CASP-1OA100 mg/kg·d, 6 wk[148]
Vascular injuryHypotensivephysiological dataphysiological dataOA, OA-Xn0.1-100 µmol/L[149]
HiperlipidemiaAnti-hiperlipidemic17 genes (microarray), CACNA-1BTC, TG, HDLC, 4 genesOA3 tablets/d , 4 wk[150]
HiperlipidemiaAnti-hiperlipidemic likely via regulation of the miR-98-5p/PGC-1b axiTC, TG, LDL, PGC-1bOA20 mg/kg, 4 wk[151]
FertilityRecovered fertilityincreasing the permeability of the germinal epitheliumOA30 mg/kg[152]
FertilityInfertility treatmentOCT-4, GDF-9, STRA-8, MVH, ZP-2, ZP-3, ITG-α6, TP-2,SCP-3, ZP-1, ITG-β1OA3 µg/mL[153]
Fertility/Reproductive functionRejuvenates testicular functionBCL-2pNF-κB, IL-1β , COX-2 TNF-α, H2AX, pP53, BAX, P38OA5-25 mg/kg·d, 24 wk[154]
Renal fibrosisAttenuates renal fibrosisNRF-2, HO, NQO-1, BAX, HSP-70BCL-2,OAN.R.[155]
NephropathyPrevent diabetic nephropathysINS, SOD, adiponectinTG, BUN, Cr, TGF-β, SMAD1/2OA100 mg/kg·d, 20 wk[156]
Renal IRIanti-Renal IRISOD, GPX, TT, eNOS, NRF-2, PPAR-γ, DDAHsCre, NGAL, TOS, NO, ADMA, NF-κB, ET-1OA-Xs20 mg/kg, 5 h before IR[157]
Nephritis Lupus/SLEInhibition of Th17 differentiationTh17, IL-17A, serum dsDNA, ROR-γtOA-Xs0-10 µmol/L, 50 mg/kg[158]
MRSAAnti-microbialMicrobe concentrationOA-Xs10-30 µg/mL[159]
Circadian clockMediates circadian clockCLOCK, ELO-VL3, TUBB-2A CLDN-1, BMA-1AMY-2A5, USP-2, PER-3,THRSPOA0.01% diet[160]
Cisplatin induced nephrotoxicityPrevent neprotoxicityMAP-1A/AB, LC1CASP-3/9, PARP cleavage, ATG-5, ERK1/2, STAT3, NF-κBOA10-40 mg/kg[161]
Dermatitis/TPA-treated mouse earsInhibit dermatitisMPO, COX-2, iNOS, TNF-a, IL-1β, pP65OA-Xn2, 5 or 10 µmol/L[162]
Diabetes induced cardiomyopathyPrevent diabetic induced cardiomyopathy via Nrf2HO-1, SOD, NRF-2,Glycogen, MDA, p-GSOA80 mg/kg·2 d, 14 d[163]
Diabetic mesangial cell injuryDiabetic renal fibrosisPI3K/AKT/mTORAutophagy, PTEN,OA10 µmol/L[164]
Gut atrophy /piglet modelPrevent gut atrophyTGR-5, FXROA50 mg/kg·d, 14 d[165]
Immune suppressionImmune suppressive, anti-RAIL-10collagen specific sIgG, CD4+ INF-γ, IL-17α, IL-2-/4/6/1β, TNF-α, GM-CSF, MCP-1 , MMP-1/3OA-Xs1-10 mg/kg 18 times between 28 and 53 d after the initial immunisation[166]
Immune suppression/glucocorticoid resistanceProtecting DEX induced GC impairmentApoptosis, GR bindingGR-αOA+I100 mg/kd·d, 21 d[167]
LongevityDAF-16, SOD-3, HSP-16.2 CTL-1OA0-600 µmol/L·2 d[168]
Metal (MeHg) toxicityMitigate low-dose MeHg toxicity.accumulation of metals in organsOA-Xs40 µg/kg[169]
Muscle AtrophyReduces denervation induced muscle atrophyCNTF, JNK-2, STAT3OA-Xs0.2-1 µmol/L[170]
Muscle atrophyAnti-muscle atrophymTORC-1/P70, S6K, PAX-7, MYO-D, MyogeninFOXO-1, MURF-1, Atrogi-n1OA-Xs1 µmol/L, 1-10 mg/kg[171]
Myocarditis - myocardial İnjuryEA myocarditisIL-10, IL-33HW/BW, BPN, IK-17, IL-6, TNF-α , GalectinOA50 mg/kg·d, 21 d or 65 d[172]
ObesityAnti-obesityoctanoylated ghrelin production, PC-1/3, PC-2OA20-40 mg/kg, 7 d[173]
ObesityImproves gustatory perception of lipids and exerts protective effects in obesityCD36blood insulin and glucose, hepat,c TG, IL-6OA0.005% (w/v) for 16 wk[174]
Renal injuryPrevent nephropathynNRF-2/tNRF-2, HO-1, KEAP-1, BAXurinary 8-OHdG and 8-iso-PGF-2 α, BCL-2OAN.R.[175]
Renal IRIAnti-Renal IRI; antioxidant, anti-inflammatory, and anti-apoptotic activitiesSOD, GPX, GSH, CAT, IL-10, NRF-2, GGLcBUN, Cr, KIM-1, LDH, MDA, IL-6, INF-γ, MPO,OA12.5-50 mg/kg·d, 15 d[176]
SepsisLung damage, experimental sepsisSOD, GPX, IL-6, IL-10, KCiNOS, NRF-2,OA10 mg/kg[177]
Vascular injuryPrevent oxidative stress induced cell injury by with AKT/eNOS signaling pathwayNO, SOD, CAT, CASP-3, FAS, FASL, BCL-2MDA, BAXOA[178]